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Objective: To evaluate the efficacy of peritumoral hyaluronic acid-cisplatin therapy in a 
murine model of laryngeal squamous cell carcinoma and to evaluate its effect on cancer 
stem cells. 
 
Study Design: An orthotopic murine study utilizing UMSCC-12 laryngeal cancer cells 
was conducted in randomized controlled fashion with three treatment arms: saline, 
systemic cisplatin, and peritumoral HA-cisplatin.  
 
Methods: UMSCC-12 laryngeal cancer cells were inoculated into the buccal mucosa of 
athymic nude mice followed by weekly treatment with saline, systemic cisplatin, or 
peritumoral HA-cisplatin for 3 weeks. Tumor response and animal weight was monitored 
and change in CD44 proportion was analyzed ex vivo.   
 
Results: HA-cisplatin demonstrated superior antitumor efficacy and greater reduction in 
CD44 positivity on ex vivo analysis.  
 
Conclusion: Peritumoral nanoconjugated HA-cisplatin provides superior antitumor 
efficacy compared to standard cisplatin therapy in an in vivo laryngeal cancer model. 
There was also selective targeting of CD44+ cancer cells with HA-cisplatin. This 
therapeutic strategy could represent the first selective laryngeal CSC-targeted therapy. 
Further preclinical investigation is warranted to evaluate its role for locally advanced 
head and neck cancer treatment. 
 
 
Key Words: Larynx cancer, cancer stem cells, targeted therapy, CD44, hyaluronan 
nanoconjugate.  
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More than 55,000 Americans are expected to be diagnosed with head and neck cancers 
in 2014, with a large proportion of these being squamous cell carcinomas1. 
Approximately 12,000 of these oral cavity, pharyngeal, and laryngeal cancer patients 
will die from their disease yearly. Although the incidence of this disease in the US has 
been noted to be relatively stable, recent studies have shown the rates of 
oropharyngeal cancers associated with HPV to be rising1. These findings suggest that 
head and neck cancer will continue to be a prominent malignancy for treatment our in 
national healthcare cancer mission.  
Historically, radiation therapy alone for patients with unresectable head and neck 
squamous cell carcinomas (HNSCC) provided unsatisfactory 5-year survival and 
recurrence rates. As a result, concurrent radiation and chemotherapy has now become 
the standard for adjuvant therapy after surgical ablation of the primary tumor and 
definitive treatment in select cases. Platinum-based chemotherapy, namely cisplatin, 
administered systemically via intravenous (IV) route remains a first line agent due to its 
radiosensitizing and cytotoxic effects2. Cisplatin therapy, however, continues to have 
significant limitations. Besides its known toxicities to the kidney, peripheral nerves and 
hearing, as a systemically delivered agent, it has poor penetration into the locoregional 
lymphatics.  Only a very small fraction of the systemic dose of the drug will be taken up 
into the lymphatics and lymph nodes, which may in part be due to monodirectional 
lymphatic flow and pressure gradients in these channels3. This is a critical factor in 
patients with locally advanced disease where lymph node metastases are a frequent 
occurrence. Another major limitation is that HNSCC has also shown marked resistance 
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to cisplatin in up to 40% of patients4, which has important implications as any efforts to 
overcome this resistance by increasing dosage has severe limitations due to the dose-
dependent toxicity of the drug5. Finally, cisplatin lacks specificity in targeting CSCs, 
considered by many to be the primary mediators of treatment failures6. Thus far, 
targeted therapy against CSCs7 is a relatively unexplored but critically important area of 
study that needs further investigation.  
HA is an endogenous polysaccharide, with alternating D-glucuronic acid and N-
acetyl D-glucosamine units, found in the extracellular matrix of connective tissues. In 
previously published work8, there were significantly increased lymphatic tissue 
concentrations of cisplatin and reduced organ toxicities with peritumoral injections of 
cisplatin conjugated to nanoscopic (25-100 nM) particles of HA (HA-cisplatin) compared 
to systemically delivered standard cisplatin therapy. In related studies investigating this 
drug in orthotopic murine models, HA-cisplatin was found to have significantly higher 
anticancer efficacy in vivo relative to conventional IV cisplatin therapy in HNSCC 
xenografts implanted in the buccal mucosa of the subject mice3,9.  
Moreover, HA is also a highly specific ligand for the CD44 surface receptors10, 
and CD44 is described as a cell surface marker specific for CSCs in HNSCC. In fact, 
CSCs were first successfully isolated from HNSCC cell lines utilizing CD44 
expression11. The interactions between these two molecules, however, are yet to be 
investigated in the setting of stem-cell targeted therapy in HNSCC. Thus, the objectives 
of this study were to evaluate the efficacy and toxicity of peritumoral HA-cisplatin 
therapy compared to standard systemic cisplatin in vivo in a laryngeal cancer xenograft 
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model via orthotopic tumor implantation, and to evaluate the effect of HA-cisplatin on 
the CD44 positive (+) HNSCC tumor population ex vivo. 
 
 




UMSCC-12 human laryngeal cancer cells were grown and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 
10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO), and 1% combination of 
penicillin and streptomycin (Sigma-Aldrich, St. Louis, MO) in 37 °C humidified 
atmosphere of 5 % CO2 in air. To utilize the cells for the various experiments, they were 
trypsinized using 0.25% trypsin (Sigma-Aldrich, St. Louis, MO), collected, and counted 
with a hemocytometer to determine the number of viable cells. 
 
In Vitro CD44 Analysis 
 
In vitro analysis was performed prior to conducting the in vivo study to ensure that the 
UMSCC-12 cell line had a relatively high CD44+ proportion of cells. To determine the 
CD44+ proportion, the cells were first trypsinized, collected, rinsed in 1x PBS, and 
placed in single-cell suspension. They were then treated with fluorochrome-conjugated 
CD44 antibody (BD Biosciences, San Diego, CA) for 30 minutes on ice. Once 
completed, the cells were rinsed again in 1x PBS and resuspended before being 
analyzed via flow cytometry (Beckman Coulter CyAn ADP analyzer, Brea, CA).  
 
Cell Viability Assay 
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To examine the in vitro effect of HA-cisplatin and standard cisplatin on the viability and 
proliferation of UMSCC-12 cells, a standard MTS assay was performed. Cells were 
seeded in 96-well plates at a density of 1000 cells per well. After a 24 hour incubation 
period, HA-cisplatin and cisplatin were added to each well in varying concentrations and 
then incubated for 72 hours. Cell viability was then quantified by the colorimetric 
CellTiter96 Aqueous MTS assay (Promega, Fitchburg, WI) at 490 nm on a BioTek 
Synergy 2 plate reader (BioTek, Winooski, VT) according to the manufacturer’s 
instructions.  
 
In Vivo Tumor Model 
 
UMSCC 12 cells were allowed to proliferate in cell culture as previously described and 
then inoculated in the buccal mucosa of 33 athymic nude female mice 4 to 6 weeks in 
age (Harlan Laboratories, Inc., Indianapolis, IN). The cells were prepared in 1x PBS 
solution at a concentration of 1x106 cells per 100 µL. Tumor inoculation was performed 
under isoflurane anesthesia using a 25-gauge needle. Tumor size and body weight 
were then measured 3 times weekly with a digital caliper. Tumor volume measured in 
cubic millimeters was calculated using the following equation:  
 
Tumor Volume = (π/6) x (Width)2 x Length.  
 
Body weight was measured in grams using a standard digital scale. Once tumor 
volumes reached 50 mm3, the mice were randomized into three treatment arms with 11 
mice in each arm: control, systemic cisplatin, and peritumoral HA-cisplatin. Subjects 
were treated weekly at 50% maximum tolerated dose (MTD) for the two treatment arms 
and with PBS for the control arm for 3 weeks. Pharmaceutical-grade cisplatin was 
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utilized for both the systemic group and in the HA-cisplatin group, with the latter 
nanoconjugated formulation synthesized as described in previously published work12. 
Treatments in the control and standard cisplatin arms were administered 
intraperitoneally and treatments in the HA-cisplatin group were administered 
subcutaneously around the tumor site. The MTD level used was 10 mg/kg per week as 
previously reported in studies where intraperitoneal cisplatin was dosed in mice13,14.  
Once the treatment period concluded, 3 mice from each arm, designated as the 
early post-treatment group, were then euthanized, the tumors were harvested, and ex 
vivo CD44 analysis of the samples were performed. The remaining subjects were then 
monitored for 9 weeks post-treatment for tumor size and body weight. At end-of-study, 4 
mice from each arm were analyzed for CD44+ cell proportion in the tumors ex vivo. 
 
Ex Vivo CD44 Analysis 
 
Harvested tumors were prepared for CD44 analysis via either Western blotting or flow 
cytometry. For Western blot analysis, proteins were collected, quantified, separated by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), and 
electrotransfered onto a Hybond nitrocellulose membrane as described in a prior 
study15. Actin levels were assessed to ensure relatively equal protein loading and 
transfer among the tumor samples. Primary mouse antibodies included anti-CD44 
antibody (#5640; 1:1,000; Cell Signaling Technology, Beverly, MA) and anti-actin 
antibody (MAB1501; 1:50,000; EMD Millipore, Billerica, MA). Secondary anti-mouse 
antibody staining was then applied at 1:5,000 for anti-CD44 antibody and 1:10,000 for 
anti-actin antibody. Both the early post-treatment and end-of-study tumor samples were 
analyzed via Western blot.  
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For flow cytometry analysis of CD44 proportion, the tumor samples were 
processed using a detailed tumor digestion protocol available via the University of 
Michigan Comprehensive Cancer Center Wicha Lab manual available online16. The 
main digestive agent utilized was 10x collagenase/hyaluronidase (STEMCELL 
Technologies Inc., Vancouver, BC, Canada) diluted 1:10 in Medium 199 (Sigma-Aldrich, 
St. Louis, MO). The resultant tumor cells were then converted to single-cell suspensions 
and treated with fluorochrome-conjugated CD44 antibody (BD Biosciences, San Diego, 
CA) and then analyzed via flow cytometry (Beckman Coulter CyAn ADP analyzer, Brea, 
CA) for CD44+ cell proportion. Of note, only the end-of-study tumor samples were large 




GraphPad Prism 6 (version 6.02; GraphPad Inc., San Diego, CA) was used to generate 
best-fit non-linear dose response curves for IC50 determination for the MTS assay data. 
Comparisons of differences between two means were determined by Student’s 
unpaired t-test via the statistical functions of Microsoft Excel 2010 software (Microsoft 
Corporation, Redmond, WA). Data are presented as mean values with error bars 





In Vitro Analysis of UMSCC-12 Cell Line 
 
Flow cytometry analysis showed the CD44+ proportion of cells in UMSCC-12 to be  
on average  61±6 % in this cell population when grown in vitro (Figure 1). The relatively    
high proportion of CD44+ cells (60%) within this cell line validated its use in the in vivo 
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model to ensure that a knockdown effect on CD44 expression could be clearly detected 
with drug treatment if such an effect occurred. To evaluate the cytotoxic effect of HA-
cisplatin on UMSCC-12 cells, the cells were plated and treated with increasing 
concentrations of HA-cisplatin as well as standard cisplatin for 72 hours with resultant 
cell viability determined by MTS assay (Figure 2). A dose dependent decrease in cell 
viability was seen with both drugs demonstrating that conjugation to HA does not inhibit 
the cytotoxic effect of cisplatin (as previously described)13. GraphPad was used to 
determine the IC50 values of the two drugs. IC50 values were comparable between the 
two treatment drugs at 3.01±0.59 µg/mL for cisplatin and 5.59±0.76 µg/mL for HA-
cisplatin (p=0.3). 
 
In Vivo Analysis of Efficacy and Toxicity 
 
To assess the overall efficacy of HA-cisplatin in vivo, an orthotopic xenograft murine 
model was utilized. Three separate treatment arms were set in randomized, controlled 
manner and these included control, standard cisplatin, and HA-cisplatin, with 11 mice in 
each group from the start. After 3 weeks of treatment, an early post-treatment group of 
3 mice from each arm were euthanized and their tumors were analyzed for CD44+ 
proportion. The remaining mice were then monitored three times a week for tumor 
volume and body weight for 9 weeks at which point the study was concluded. HA-
cisplatin showed superior antitumor efficacy compared to cisplatin as shown by tumor 
volumes at 4 weeks post-treatment (39.2mm3 vs. 57.6mm3, p = 0.02)  but at end-of-
study the difference was not significant (77.5mm vs. 105.6mm3, p = 0.05) (Figure 3). 
Tumor volumes in the control group demonstrated an exponential growth curve 
approximately 4 weeks after completion of treatment. The tumor volumes in both 
Page 9 of 29
John Wiley & Sons
The Laryngoscope












treatment arms, in contrast, were initially more stable followed by a shallow linear 
growth rate. One study subject in the HA-cisplatin arm experienced a complete 
response (CR) and one had a sustained partial response (PR) (Figure 4). None of the 
standard cisplatin mice had CR or PR. In evaluating toxicity, animal weights were found 
to be similar between the cisplatin and HA-cisplatin arms at 24.7±0.69 grams and 
24.5±0.81 grams, respectively (Figure 5).  
 
Ex Vivo Analysis of CD44 
 
In the early post-treatment group, CD44 reduction was seen in both treatment groups, 
but to a greater degree with HA-cisplatin as demonstrated by Western blotting (Figure 
6). At end-of-study, 4 mice from each arm were then euthanized and tumors were 
analyzed for CD44+ proportion, both by flow cytometry and Western blotting (Figure 7 
and 8). Long-term durability of this CD44 knockdown effect was seen end-of-study in 
the HA-cisplatin group compared to cisplatin (8.1%CD44+ vs. 23.9%CD44+, p = 0.02) 
which was similar to control (23.9%CD44+ vs. 24.8%CD44+, p = 0.86). The flow 
cytometry data was confirmed by the Western blot results which clearly demonstrated 
reduced expression of CD44 in the HA-cisplatin group which was maintained even 8 





Concurrent chemoradiation therapy has lead to improved locoregional disease control 
compared to monotherapy and is currently the standard of care for locally advanced 
HNSCC patients following surgery. Even with these advancements, however, survival 
rates for patients with HNSCC have improved little the last three decades. In efforts to 
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improve outcomes, there have been several Phase III trials that implemented cisplatin in 
combination with one or more drugs, such as 5-fluorouracil. Some studies showed 
promising results, but others showed only minimal improvement in disease-free survival 
and locoregional control compared to patients receiving radiation therapy alone2,17,18.  
This grim clinical picture of HNSCC supports the vital need for discovery and 
development of better treatments, and improved drug-delivery over traditional systemic 
therapy administered intravenously. A locoregionally-directed drug-delivery, such as 
nanoconjugated HA-cisplatin via a weekly peritumoral injection, as was utilized in this 
study, may be an important treatment advance in a thus far stagnant paradigm of 
treatment for advanced HNSCC. While localized therapy is already being used in the 
treatment of esophageal cancers, limb-limited melanoma with limb perfusion 
techniques, and hepatic cancers via (transarterial) TACE techniques19,20, this 
therapeutic strategy has yet to be clinically implemented in the treatment of HNSCC.  
The current study demonstrates the improved in vivo efficacy of localized, 
peritumoral HA-cisplatin therapy compared to systemic cisplatin therapy, especially in 
the early post-treatment period. The difference in tumor volume between the two 
treatment groups, however, was not statistically significant by end-of-study. It is 
important to note, though, that one mouse in the HA-cisplatin arm had a complete 
response with no evidence of residual tumor and one other had a sustained partial 
response at end-of-study. No mice in the standard cisplatin arm experienced such a 
response. But the overall efficacy of standard cisplatin in this study utilizing a laryngeal 
cancer cell line is not surprising given its proven efficacy clinically in the setting of 
advanced laryngeal cancer treatment. In fact, in some institutions, systemic cisplatin is 
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used as a chemo-selection agent to determine candidacy for organ preservation therapy 
as an alternative to total laryngectomy in patients with advanced laryngeal squamous 
cell carcinoma21.   
The natural progression of HNSCCs is to preferentially spread to the locoregional 
lymphatic basins. Hematogenous spread is less frequent than lymphatic spread in 
squamous cell carcinomas22. Despite this, systemic IV therapy has remained the 
standard modality of treatment. Locoregional peritumoral therapy delivers drug into the 
lymphatic channels, directly affecting the primary tumor and its associated lymphatic 
basins. This could prove to be the more effective strategy against locally advanced or 
recurrent disease in the future. The current study did not incorporate the treatment of 
nodal disease to the in vivo model, mainly due to the low in vivo metastatic potential of 
the UMSCC-12 cell line. Previously published studies on HA-cisplatin, however, 
demonstrat d efficacy of peritumoral HA-cisplatin therapy even at the regional nodal 
basins3,9. This suggests that HA-cisplatin could prove to be an effective therapy in 
locoregionally advanced HNSCCs in the human translational setting with potential to 
even improve survival rates in this subset of patients.  
Solid tumors, including HNSCCs, normally consist of a heterogeneous population 
of cell types including tumor, stromal, and inflammatory cells6. Among the tumor cells, 
CSCs represent a small subpopulation of cells that have the unique ability to self-renew 
through multiple generations, regenerate cells that have both tumorigenic and non-
tumorigenic properties, and sustain growth of the tumor23-27. This subpopulation is 
responsible for most of the growth and spread of tumor, with the non-CSC population 
having limited to no growth potential11. Analogous to normal stem cells, CSCs can lie 
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quiescent for periods of time and harbor mechanisms to protect against DNA and 
cellular damage6. Given these properties, it is not surprising that CSCs have been 
shown to have resistance against chemotherapeutic agents and external beam 
radiation28,29.  An additional feature of CSCs is that they can be isolated from the other 
tumor cell types by distinctive cell surface markers, namely CD44 and ALDH in HNSCC. 
In fact, CSCs were first successfully isolated from HNSCC cell lines utilizing CD44 
expression11. It is theorized that treatment failures are due to a failure in targeting and 
eliminating CSCs resulting in tumor regrowth and resistance to therapy30.  
Coincidentally, HA nanoconjugation, which allowed for cisplatin to be 
administered via peritumoral route, also provided the potential for HA-cisplatin to 
preferentially target the CD44+ subpopulation, and thus, the CSCs in a tumor. The 
results of the current study showed significant evidence of this selective CD44-targeting 
by HA-cisplatin. The early post-treatment tumors showed decreased expression of 
CD44 in the HA-cisplatin treated group compared to cisplatin-treated mice and controls 
according to Western blot analysis. The end-of-study tumors showed significant 
reduction in CD44+ cell proportion via flow cytometry in the HA-cisplatin treated 
populations, and these findings correlated with the Western blot analysis. It is important 
to note, however, that although decrease in CD44 positivity allows one to infer effective 
CSC-targeting, a more accurate way to determine this would incorporate assessing for 
both CD44 and ALDH positivity. Overall, these results provide the preliminary basis for 
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Peritumoral nanoconjugated HA-cisplatin provides superior antitumor efficacy 
compared to standard cisplatin therapy in an in vivo laryngeal cancer xenograft model. 
Moreover, it may potentially target laryngeal CSCs as evidenced by its selective effect 
on CD44+ cells within a heterogeneous tumor population. These results provide support 
for further translational investigation of this treatment modality as a potential CSC-
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Figure 1. One sample of CD44+ cell proportion in UMSCC-12 cell culture population in 
vitro as determined by flow cytometry.   
 
Figure 2. Best-fit non-linear dose response curves showing dose-dependent decrease 
in cell viability of UMSCC-12 cells with drug treatment.  
 
Figure 3. Tumor response curves for the three treatment arms.   
 
Figure 4. Examples of subject mice. A, a cisplatin mouse early after completion of 
treatment. B, a HA-cisplatin mouse with partial response. C, a control mouse showing 
uninhibited tumor growth.  
 
Figure 5. Weights of animal subjects monitored throughout the study.  
 
Figure 6. Western blot from early post-treatment group demonstrating reduction of 
CD44 expression in the two treatment arms, but to greater degree in HA-cisplatin.   
 
Figure 7. A, Flow cytometry data from end-of-study group demonstrating significant 
reduction of CD44 expression in the HA-cisplatin.  B, Examples of flow cytometry 
diagrams from each group.  
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Figure 8. Western blot from end-of-study group demonstrating reduction of CD44 
expression in HA-cisplatin group.  
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Figure 1. One sample of CD44+ cell proportion in UMSCC-12 cell culture population in vitro as determined 
by flow cytometry.  
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Figure 2. Best-fit non-linear dose response curves showing dose-dependent decrease in cell viability of 
UMSCC-12 cells with drug treatment.  
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Figure 3. Tumor response curves for the three treatment arms.  
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Figure 4. Examples of subject mice. A, a cisplatin mouse early after completion of treatment. B, a HA-
cisplatin mouse with partial response. C, a control mouse showing uninhibited tumor growth.  
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Figure 5. Weights of animal subjects monitored throughout the study.  
216x161mm (150 x 150 DPI)  
Page 26 of 29
John Wiley & Sons
The Laryngoscope













Figure 6. Western blot from early post-treatment group demonstrating reduction of CD44 expression in the 
two treatment arms, but to greater degree in HA-cisplatin.  
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Figure 7. A, Flow cytometry data from end-of-study group demonstrating significant reduction of CD44 
expression in the HA-cisplatin.  B, Examples of flow cytometry diagrams from each group.  
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Figure 8. Western blot from end-of-study group demonstrating reduction of CD44 expression in HA-cisplatin 
group.  
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